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Proteolysis inhibition by 
hibernating bear serum leads to 
increased protein content in human 
muscle cells
Stéphanie Chanon1, Blandine Chazarin2,3,4, Benoit Toubhans1, Christine Durand1, Isabelle 
Chery2,5, Maud Robert1,6, Aurélie Vieille-Marchiset1, Jon E. Swenson7,8, Andreas Zedrosser9,10, 
Alina L. Evans11, Sven Brunberg7, Jon M. Arnemo11,12, Guillemette Gauquelin-Koch4, Kenneth 
B. Storey13, Chantal Simon1, Stéphane Blanc2,5, Fabrice Bertile2,3 & Etienne Lefai  1
Muscle atrophy is one of the main characteristics of human ageing and physical inactivity, with resulting 
adverse health outcomes. To date, there are still no efficient therapeutic strategies for its prevention 
and/or treatment. However, during hibernation, bears exhibit a unique ability for preserving muscle 
in conditions where muscle atrophy would be expected in humans. Therefore, our objective was to 
determine whether there are components of bear serum which can control protein balance in human 
muscles. In this study, we exposed cultured human differentiated muscle cells to bear serum collected 
during winter and summer periods, and measured the impact on cell protein content and turnover. In 
addition, we explored the signalling pathways that control rates of protein synthesis and degradation. 
We show that the protein turnover of human myotubes is reduced when incubated with winter bear 
serum, with a dramatic inhibition of proteolysis involving both proteasomal and lysosomal systems, 
and resulting in an increase in muscle cell protein content. By modulating intracellular signalling 
pathways and inducing a protein sparing phenotype in human muscle cells, winter bear serum therefore 
holds potential for developing new tools to fight human muscle atrophy and related metabolic 
disorders.
Muscle disuse atrophy is common in humans during immobilization, bedrest, spaceflight, denervation, cancer, 
and ageing, and therefore represents a major health issue1–3, and is also observed in a number of non-human 
models used for atrophy studies4. Basic knowledge regarding the underlying mechanisms is continuously grow-
ing, and an intricate network of signalling pathways appears to be involved in the regulation of muscle fibre 
size, including IGF1-AKT-FOXO, inflammatory cytokines, NFκB signaling, myostatin, and glucocorticoids5. 
However, there is still no fully effective therapy or prevention for disuse atrophy.
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In humans, bed-rest and inactivity result in the loss of up to 30–40% of muscle volume after 2–4 months of 
disuse6–8, and this loss of muscle strength reaches 54% after 3 months of disuse6. Physical inactivity and associ-
ated loss of muscle mass and strength have severe deleterious consequences for metabolism and health, inducing 
metabolic inflexibility that could develop into a reduction in the capacity to oxidize lipid fuels, insulin resistance, 
and ectopic storage of fat9. In contrast, minimal or no loss of skeletal muscle mass and strength has been observed 
in several species during hibernation, despite prolonged disuse and fasting. Among them, bears (family Ursidae) 
are quite spectacular in this regard. They remain inactive up to seven months during the denning period, without 
eating, drinking, urinating, or defecating, and without arousal episodes10–12. Yet, a very low loss in protein content 
(from 4% to 17%) is reported in early winter, and this value remains uniquely stable during the following 3–4 
months, whereas muscle and fibre cross-sectional area is preserved13–15, and muscle strength only decreases by 
23%15.
The underlying protein sparing mechanisms in bears have yet to be discovered. So far, the current hypotheses, 
including recycling of nitrogen11,16–18 and existence of a specific antioxidant strategy, still require deeper examina-
tion. Strikingly, bear skeletal muscles are resistant to the atrophic effects of denervation in winter, but not in sum-
mer19, suggesting that the nervous system is not directly involved. The direct corollary is the possible role of still 
unknown humoral factors in controlling bear muscle adaptive responses to hibernation. In support of this view, 
winter bear plasma has been reported to induce a 40% decrease in the net proteolytic rate in isolated rat muscles20, 
indicating the presence of circulating factors possibly able to trigger protein sparing during hibernation.
In this study, we exposed cultured human differentiated muscle cells to bear serum collected in winter and 
summer periods (WBS and SBS, respectively), and measured the impact on cell protein content and turnover. In 
addition, we explored the signalling pathways that control rates of protein synthesis and degradation. Our results 
highlight how serum from hibernating bears is able to trigger trans-species effects, hence being a potential source 
for new therapeutic molecules to fight human muscle atrophy and associated metabolic disorders.
Materials and Methods
Bear sample collection. Free-ranging sub-adult (2- to 3-year-old) brown bears (Ursus arctos; 16 females 
and 6 males) were captured during both their active (summer) and inactive (winter) periods in Dalarna and 
Gävleborg counties, Sweden (see Table 1 for bear characteristics). The same bears were immobilized during win-
ter (February) and recaptured during summer (June), as described previously21,22. Blood samples were collected 
from the jugular vein in tubes containing a clot activator (VenosafeTM VF-109SP, Terumo) within 20 min after 
darting, then centrifuged (2000g, 10 min) within 1 hour after sampling, and serum was immediately frozen on 
dry ice until storage at −80 °C. The study was approved by the Swedish Ethical Committee on Animal Experiment 
Year of 
collection Id Number Age (years) Gender
Winter 
weight (kg)
Summer 
weight (kg) Mixes
2011 W1015 2 M 25 27
M1W
&
M1S2012
W1017 3 F 56 55
W1105 2 F 31.5 na
W1104 2 F 30.2 29
W1110 2 F 27.3 29
2013
W1105 3 F 55 60
M2W &
M2S
W1207 2 M 54 64.5
W1110 3 F 53 58
W1104 3 F 52 57
W1202 3 F 48 48
W1204 2 M 40 38
W1209 2 F 30 27
2014
W1303 2 F 36 43
M3W & 
M3S
W1317 2 M 33 40
W1305 2 F 37 49
W1303 2 F 36 43
W1317 2 M 33 40
2016
W1404 3 M 50 68
M4W &
M4S
W1407 3 F 74 83.6
W1509 2 F 25 37.8
W1511 2 F 29 41
W1512 2 F 36 51.2
N = 22 2.3 ± 0.1 16 F/6 M 40.1 ± 2.8 46.7 ± 3.2
Table 1. Characteristics of the brown bears used in this study. A total of 22 pairs of bear serum (winter and 
summer) were collected during the indicated years. Equal volumes of serum were used to obtain four different 
mixes (M1W to M4W) of winter bear serum (WBS) and four paired mixes (M1S to M4S) of summer bear 
serum (SBS). All experiments presented in this study were performed with each of the mixes as replicates. 
Averages are given as mean ± SEM.
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(applications #C212/9, #C47/9, #C7/12, #C268/12, and #C18/15), the Swedish Environmental Protection Agency 
(NV-0758-14), and the Swedish Board of Agriculture (31- 11102/12). All procedures complied with Swedish laws 
and regulations.
We prepared different mixes of winter bear serum (WBS) and of summer bear serum (SBS) using the indi-
vidual bear samples (Table 1). It is important to note that serum samples were collected from the same animals 
during both seasons, and that both summer and winter mixes were obtained by pooling the exact same volume of 
serum for all bears. Detailed characteristics of the sera in terms of metabolite and hormone levels and more global 
proteomic compositions have been published previously from the same bear population23,24.
Culture of human skeletal muscle cells and treatments with bear serum mixes. Human muscle 
cells were derived from vastus lateralis muscle biopsies obtained from healthy control donors (Diomede exper-
imental protocol). All procedures were approved by the French Ethical Committee SUD EST IV (Agreement 
#12/111 A 13-02) and performed according to the French legislation (Huriet’s law). All patients gave their written 
consent after being informed of the nature, purpose, and possible risks of the study. The myoblasts were purified 
and differentiated into myotubes according to the procedure previously described in detail25. After five days of dif-
ferentiation in the standard differentiation medium (DMEM medium), containing glucose (1 g/l) and fetal bovine 
serum (FBS, 2%), myotubes were washed with phosphate-buffered saline (PBS) and then incubated at 37 °C with 
5% of either SBS or WBS. The 5% concentration of bear serum was chosen on the basis of the previous work from 
Fuster et al.20, who tested the effects of plasma on ex vivo rat muscles. A control group was set as myotubes kept in 
differentiation medium containing 2% fetal bovine serum (FBS condition). For all experiments, repetitions were 
performed on cell preparations coming from different donors.
Myosin heavy chain imaging and cell surface determination. After exposure to FBS, SBS or WBS 
(48 h), human muscle cells were washed twice with PBS and fixed with 4% formaldehyde for 10 min, then per-
meabilized with 0.1% Triton X-100/PBS for 15 min and blocked by 1% bovine serum albumin for 30 min at 
room temperature. Myosin heavy chain protein of human myotubes was detected with primary antibody MF-20, 
followed by a secondary antibody Alexa Fluor® 555 Anti-Mouse IgG (H + L) incubation. Then, the area occu-
pied by myotubes was measured, as described in detail previously26. For each well, corresponding to one mix 
applied to one cell preparation, at least ten pictures were taken to determine the percentage of surface occupied 
by myotubes.
Measurement of protein degradation and synthesis rates. Protein degradation rates were assayed, 
as previously described26. Human muscle cells were first incubated for 24 hours with [3H]-L-Tyrosine (2 μCi/
ml), then washed three times with PBS, and shifted in chase medium (containing nonradiolabeled tyrosine) for 
two hours. The release of TCA-soluble radioactivity in the culture medium was assayed for the 6 hours following 
24 hours of incubation in SBS and WBS conditions to determine the rate per hour of free tyrosine release. The 
total amount of incorporated radioactivity was then determined in the whole cell culture to calculate the degra-
dation rate relative to the amount of labeled protein, expressed in percentage per hour. Protein degradation rates 
were also measured in the presence of proteasome (Bortezomib/PS-341, 1 μM) and lysosome (Concanamycin A, 
0.1 μM) inhibitors, as previously described27. Briefly, after cell protein labeling (24 hours, see above), inhibitors 
or DMSO were added to FBS, SBS and WBS conditions one hour before monitoring the release of TCA-soluble 
radioactivity for 6 hours. All procedures were repeated with three different primary myotube preparations.
Protein synthesis rates were assessed using two different procedures. Incorporation of radiolabeled tyrosine 
was monitored, as already described26. Briefly, myotubes were exposed to SBS and WBS for 24 or 48 hours, and 
[3H]-L-Tyrosine (2 μCi/ml) was then added to the medium. After 2 hours incubation, cells were scraped in 10% 
TCA to precipitate proteins. The pellet was resuspended in lysis buffer (Tris-HCl 20 mM, NaCl 138 mM, KCl 
2.7 mM, MgCl2 1 mM, Glycerol 5%, NP 40 1%, EDTA 5 mM, Na3VO4 1 mM, NaF 20 mM and DTT 1 mM), and 
protein concentration and radioactivity were quantified. Protein synthesis rates are presented as means ± SEM of 
at least three determinations with different myotube preparations. We also used puromycin incorporation assays 
to determine protein synthesis rates using the SunSET method28. Cells were exposed to SBS and WBS for 24 or 
48 hours and puromycin (5 μM) was added for the last 30 minutes. Measurements for the FBS condition were only 
performed after 48 hours. Cells were then scraped in lysis buffer to extract proteins. After quantification, 20 μg of 
proteins were immunoblotted using an anti-puromycin antibody (see western blot procedures).
Western blotting. After bear serum incubation, cells were scraped into 200 μl of ice-cold lysis buffer 
(TRIS-HCl 20 mM, NaCl 138 mM, KCl 2.7 mM, MgCl2 1 mM, Glycerol 5%, NP 40 1%, EDTA 5 mM, Na3VO4 
1 mM, NaF 20 mM and DTT 1 mM) supplemented with a protease inhibitor cocktail (Sigma-Aldrich, France). 
Protein concentration was determined by Bradford quantification. Western blotting was performed, as described 
previously29, loading 20 μg of total protein on precast gels (Mini-protean TGX Stain-freeTM gel, Biorad, France). 
After migration, gels were UV exposed for 3 minutes and pictures were taken for further quantification of protein 
loading. After semi-dry transfer, all membranes were blocked with 4% BSA (Bovine Serum Albumin, Euromedex, 
Souffelweyersheim, France) before incubation with primary antibodies (see Table S1). Corresponding secondary 
HRP antibodies were used for chemiluminescence revelation (Chemidoc Bio-Rad).
Quantification of mRNAs by real-time RT-PCR. Total RNA was isolated using the TRIzol reagent 
(Invitrogen, Courtaboeuf, France) according to the manufacturer’s instructions. RT-qPCR was performed as pre-
viously described29. TBP (Tata-box Binding Protein) mRNA levels were determined in each sample and was used 
as internal standard for normalization. No change in TBP expression was found comparing FBS, SBS and WBS 
conditions. The primers and real-time PCR assay conditions are listed in Table S2.
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Statistical analysis. All data are presented as means ± SEM, and fold change always related to the SBS con-
dition. To compare the SBS and WBS conditions, statistical significance was determined using paired student 
t-tests, with * indicating a p value < 0.05, **p < 0.01, and NS not significant.
Results
Human muscle cells exposed to WBS exhibit higher protein content. To evaluate the ability of bear 
serum to impact human muscle cell protein content, we first incubated quiescent differentiated polynucleated 
myotubes with bear serum collected in winter during hibernation and in summer during their active period. 
After 48 hours, we determined the cell content of heavy chain myosin by immunofluorescence and quantified 
myotube surface area (Fig. 1). While no difference could be observed between FBS and SBS conditions, the WBS 
treatment induced a significant increase in muscle cell surface area (+21.7 ± 7.2% p = 0.015) compared to SBS, 
indicating higher protein content.
Reduced protein turnover in human myotubes exposed to WBS compared to SBS. To investi-
gate the mechanisms driving the change in protein content of treated human myotubes, we next determined the 
rates of protein synthesis and degradation. Whereas incubation with SBS did not change the degradation rate 
compared to standard culture conditions (FBS condition), a 33% lower protein degradation rate (0.56 ± 0.04 
vs 0.37 ± 0.06, p = 003) was recorded after 24 hours of incubation with WBS compared to the SBS condition 
(Fig. 2A). To determine whether this could be related to proteasomal and/or lysosomal pathways, we next meas-
ured degradation rates in the presence of proteasome (PS-341, Bortezomid) or lysosomal proton pump (concan-
amycin A) specific inhibitors. Calculation of the inhibitor-sensitive fraction by subtracting the rates of proteolysis 
in cells treated with inhibitors from those in untreated cells then represented the actual contribution of each path-
way in the total degradation process. As shown in Fig. 2B, the contribution of both proteasomes and lysosomes to 
the degradation rates were dramatically decreased (−47% and −71%, respectively) in human myotubes exposed 
to WBS compared to the SBS condition, thus showing the involvement of both systems in the response to WBS.
We next quantified protein synthesis rates in myotubes exposed to bear serum by measuring the incorporation 
of puromycin (Fig. 2C,D). SBS did not change protein synthesis rates compared to standard culture conditions 
(FBS condition) whereas the puromycin incorporation was significantly decreased under the WBS condition. 
The same result was observed when measurements were performed using incorporation of [3H]-tyrosine into 
neosynthesized proteins. A mild but significant decrease was found only after 48 hours of treatment in WBS- 
compared to SBS- treated cells (Fig. 2E), while after 24 hours of treatment, rates were slightly, but not significantly, 
lower (Fig. 2F). The human myotubes exposed to WBS thus displayed a mildly reduced rate of protein synthesis, 
whereas protein degradation was dramatically inhibited.
Effects of WBS on proteasomal and lysosomal degradation pathways. To explore the 
ubiquitin-proteasome system in myotubes exposed to bear serum, we first quantified the level of ubiquitinated 
proteins in human myotubes under FBS, SBS and WBS conditions (Fig. 3A). Comparing SBS and WBS condi-
tions, no differences could be found in the control (veh) and lysosomal inhibition (Conc.A) conditions, whereas 
proteasome inhibition (PS-341) promoted an increase in the amount of ubiquitinated protein (Fig. 3B). In this 
latter condition, the increase was significantly reduced in the WBS compared to SBS condition, suggesting that 
WBS alone lowers proteasome activity. The overall process from ubiquitin ligation to protein degradation was 
explored with the quantification of the mRNA levels of ubiquitin (UBB), E2 Ubiquitin-Conjugating Enzyme 
B (UBE2B), the proteasome subunit alpha1 (PSMA1), and muscle specific E3 ligases TRIM63 and FBXO32 
(Fig. 3C,D). Expression levels of all of these messengers were similar in SBS and WBS conditions, indicating that 
lower proteasomal degradation due to WBS treatment was unlikely to originate from transcriptional regulations 
and would most likely be due to lower activities of related components.
Figure 1. Winter bear serum promotes an increase in human muscle cell size. Illustrative immunodetection 
and corresponding quantification of myosin heavy chain in cultured myotubes upon standard culture condition 
with fetal bovine serum (FBS), winter bear serum (WBS) or summer bear serum (SBS) treatment. Results are 
the mean ± SEM of 6 independent experiments (different cell preparations and bear serum mixes). Scale bar: 
100 µm. Significant differences result from paired T-tests (*p < 0.05).
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Autophagy was investigated by quantification of SQSTM1 (p62) protein and LC3II/I ratios (Fig. 4A–C). 
During induction of the autophagosomal process, SQSTM1 binds the ubiquitinated proteins and LC3I is lipi-
dated to LC3II, resulting in an increase in the LC3II/I ratio. We observed a highly significant lower abundance 
in SQSTM1 under WBS versus SBS conditions, whereas LC3b II/I ratios were not significantly decreased. At the 
mRNA level, expression of the E2-conjugating enzyme ATG3, and the lysosomal hydrolase cathepsin L (CTSL) 
were quantified in WBS- and SBS-treated cells (Fig. 4D). Whereas ATG3 expression was not modified, expression 
of CTSL was lower in the WBS condition, which would be in line with reduced lysosomal protein degradation.
Effects of WBS on protein metabolism signaling pathways. Intracellular signaling pathways were 
investigated by the quantification of the phosphorylated fraction of several key actors involved in the regulation 
of protein turnover (Fig. 5). The fraction of phosphorylated PKB (protein kinase B), but not mTOR (mechanistic 
Target of Rapamycin), was found at higher levels in WBS- than SBS-treated cells. Accordingly, the downstream 
target FOXO3 (Forkhead box O3) was also found to be hyper-phosphorylated and thus presumably inactivated in 
the WBS condition. Meanwhile, similar phosphorylation levels of serum/glucocorticoid-induced kinase 1 (SGK1) 
were recorded in SBS and WBS conditions, indicating that it might not participate in the higher phosphorylation 
level of FOXO3 that we observed upon WBS exposure. Finally, the levels of phosphorylation of S6K (riboso-
mal protein S6 kinase) and GSK3beta (glycogen synthase kinase 3ß) were found to be not statistically different 
between SBS and WBS conditions.
Discussion
Despite prolonged periods of fasting and inactivity, conditions which induce dramatic muscle wasting in 
humans30,31, the muscle mass and strength of hibernating bears are remarkably well preserved14,32–34. This 
Figure 2. Winter bear serum inhibits protein degradation and synthesis rates in human muscle cells. Overall 
protein degradation rates in human myotubes exposed for 24 hours to FBS, SBS or WBS (A), and rates of 
proteolysis after proteasomal or lysosomal inhibition (B) were measured. For the latter, twenty-four hours 
after serum exposure, inhibitors (1 µM Bortezomid [PS-341], 0.1 µM concanamycin [Conc. A], or DMSO 
only [Veh.]) were added, and rates of proteolysis were determined for six hours. Proteasomal and lysosomal 
degradation rates were expressed as the difference between total and specifically inhibited rates. Overall protein 
synthesis rates were assessed in human myotubes with quantification of puromycin incorporation after 48 hours 
of exposure to FBS, SBS or WBS (C,D). Protein synthesis rates were also assessed by measuring [3H]-tyrosine 
incorporation in human myotubes exposed for 48 hours to SBS or WBS (E). (F) Shows incorporation rates of 
[3H]-tyrosine and puromycin after 24 hours. Results are the mean ± SEM of at least 3 independent experiments 
measured in duplicate. Significant differences result from paired T-tests (*p < 0.05; **p < 0.01).
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Figure 3. Winter bear serum inhibits proteasomal degradation in human muscle cells. Illustrative 
immunodetection (A) and corresponding quantification (B) of ubiquitinated proteins in human myotubes 
exposed for 24 hours to FBS, SBS or WBS. Quantifications were performed after one hour of proteasomal (1 µM 
Bortezomid [PS-341]) or lysosomal (0.1 µM concanamycin [Conc. A]) inhibition, and in control conditions 
(DMSO only [Veh.]). Myotube expression levels of muscle specific E3-specific ligase FBXO32 (MuRF1) and 
TRIM63 (Atrogin-1) (C), and of ubiquitin (UBB) and two components of the proteasome system (UBE2B and 
PSAM1) were measured by RT-qPCR, normalized against TBP mRNA levels, and expressed as a fold change 
relative to the SBS condition. Results are the mean ± SEM of at least 3 independent experiments. Significant 
differences result from paired T-tests (*p < 0.05).
Figure 4. Winter bear serum impacts main factors of autophagy/lysosomal degradation in human muscle cells. 
Illustrative immunodetection (A) and corresponding quantification (B) of SQSTM1 (p62) and the LC3b II/I 
ratio in human myotubes exposed for 24 hours to SBS or WBS (C). Myotube expression of CTSL and ATG3 was 
measured by RT-qPCR, normalized against TBP mRNA levels, and expressed as a fold change relative to the SBS 
condition (D). Data are the mean ± SEM of at least 3 independent experiments. Significant differences result 
from paired T-tests (*p < 0.05; **p < 0.01).
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preservation is part of an overall adaptation scheme in which energy and metabolic changes are triggered in the 
cardiovascular system, kidney, liver, and intestine (microbiota). In this regard, the coordination of tissue and 
organ functions may involve circulating factors, and winter bear plasma has been reported to decrease the net 
proteolytic rate in isolated rat muscles20. As a new approach to overcome the lack of efficient treatment or preven-
tion of human muscle disuse-induced atrophy, we explored here how WBS can affect protein turnover in human 
muscle cells, studying protein synthesis and degradation, as well as key actors involved in regulating pathways. 
To examine if circulating factors could impact human muscle cell physiology, we choose to incubate cells with 
bear serum rather than plasma that may contain coagulation inhibitors susceptible to induce effects per se like 
alteration of enzyme activities. Application of WBS to human myotubes resulted in a unique situation, where a 
marked inhibition of proteolysis and a slight decrease in protein synthesis were observed. The resulting positive 
balance in protein turnover led to a higher protein content in muscle cells.
Muscle protein turnover is a tightly regulated process, the equilibrium between catabolic and anabolic path-
ways being under the control of several endocrine, paracrine, and autocrine factors (for review see5,35–38). In any 
situation of muscle atrophy, whether it results from immobilization, denervation, fasting, ageing (sarcopenia), 
inflammation, or cancer (cachexia), muscle protein degradation is activated through two intricate systems: the 
ubiquitin proteasome and autophagy systems39,40. We show here that, in human myotubes, both proteasomal and 
lysosomal system activities were reduced in the WBS condition compared to SBS. Considering signaling path-
ways, the canonical PKB actor was found activated and accordingly, the downstream FOXO3 transcription factor 
Figure 5. Winter bear serum activates mTOR/PKB pathways in human muscle cells. Illustrative blots and 
corresponding quantification of mTOR, PKB, FOXO3a, S6K, GSK3beta, SGK and their phosphorylated forms. 
Results are the mean ± SEM of at least of 3 independent experiments. Significant differences result from paired 
T-tests (*p < 0.05).
www.nature.com/scientificreports/
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was inactivated by higher phosphorylation. Coordinated activation of this signaling pathway may thus explain 
most of the observed effects on the proteasomal and lysosomal systems, considering their role in the control of 
protein degradation and regulation of muscle mass5,27,36,41.
Inactivation of FOXO3 is consistent with the recent demonstration of FOXO4 inactivation in hibernating 
squirrels42. Although serum/glucocorticoid-induced kinase 1 (SGK1) has been shown to be involved in the pre-
vention of atrophy in hibernating 13-lined ground squirrels34,43, we recorded similar phosphorylation levels of 
SGK1 in myotubes exposed to either SBS and WBS conditions. Thus, in our human muscle cell model, SGK1 may 
not participate in the regulating the higher phosphorylation level of FOXO3 that we observed upon WBS expo-
sure. The observed increase in PKB phosphorylation of treated myotubes could also reflect the modified insulin 
sensitivity of the bear skeletal muscle tissue during hibernation44 and highlights a promising future in the field of 
human diabetes.
Among the few factors inhibiting muscle proteolysis described to date, insulin and amino-acids are the best 
characterized45–48. Their circulating levels are increased in the post-prandial situation, at the same time substrates 
and energy are available for muscle protein metabolism47,49. These anabolic conditions trigger activation of the 
PKB/mTOR pathway, with subsequent inhibition of proteolysis and concomitant activation of proteosynthesis. 
Strikingly, we found an activation of PKB with positive consequences on protein content in human myotubes 
exposed to WBS, despite the fact that the serum originated from animals that had been food deprived and phys-
ically inactive for at least three months. How WBS can mimic an anabolic situation for human cultured muscle 
cells remains to be elucidated. Moreover, considering the ability of WBS to reproduce in treated human cells the 
regulation of protein turnover already described in hibernating bear muscle (i.e. lower synthesis and lower deg-
radation rates13), it is highly probable that the maintenance of muscle mass during bear hibernation involves one 
or several circulating factors.
To explain how WBS can activate PKB, leading to FOXO inactivation and protein degradation inhibition 
in human muscle cells, active circulating factors may be sought among those whose concentrations are known 
to change between seasons, either due to the central regulation of hibernation via the hypothalamic-pituitary 
axis50,51, and/or in relation to the nutritional status of the animals through their gut-liver axis52,53. Although sev-
eral differences have already been highlighted in the blood composition of active and hibernating bears11,23,24,51–57, 
no particular factors have yet been identified that specifically control muscle adaptive responses. Serum conveys 
hormones and growth factors that are major actors in muscle mass regulation58,59. However, considering the 
reduced metabolic rate in hibernating bears60, it is difficult to imagine an increase in such factors during winter. 
Of note, higher levels of blood proteins and hematocrit have been reported during hibernation23, which can likely 
be attributed to dehydration in hibernating bears. Such seasonal changes may lead to higher concentrations of 
circulating factors during winter, without any change in their production or clearance.
Among the circulating components that are known to show seasonal regulation in bears, fatty acids, whose 
composition are changed due to prolonged fasting, could play a role. Lipids are known regulators of muscle 
mass61, notably through saturated fatty acids and their ability to generate ceramides. Whereas both lipid classes 
negatively affect muscle mass, the positive impact of other lipid moieties cannot be excluded. Notably ketone 
bodies could be involved, since their circulating levels are increased by fasting62,63 and hibernation64, and they 
are known to be involved in the regulation of muscle mass65. In hibernating bears, fasting is also associated with 
modifications in urea and nitrogen metabolism66. The role of specific amino acids can not be ruled out, such as 
BCAA67 or citrulline68, even if supplementation experiments have not yet produced conclusive results. Finally, 
from the recent proteomic characterization of WBS and SBS69, it has been proposed that α2-macroglobulin, a 
non-specific protease inhibitor that exhibits higher circulating levels in winter bears, could be involved in the 
reduction in protein degradation in isolated rat muscle when incubated with winter bear plasma20. Therefore, 
α2-macroglobulin could be involved in the reduced proteolysis of human muscle cells that we observed here 
upon WBS treatment.
In conclusion, the circulating components that induce the potent trans-species effects on human muscle cells 
and that make their phenotype closely mimic that of winter bear muscles are probably those that are responsible 
for the maintenance of muscle mass and strength in hibernating bears. Their identification will no doubt pave 
the way for a new field of studies that will investigate novel solutions to prevent and/or reverse muscle atrophy in 
humans.
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